Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.08 per share a year ago.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) missed earnings with its latest quarterly results, disappointing overly-optimistic forecasters. It definitely looks like a negative result overall with ...

Good day and thank you for standing by. Welcome to the Akebia's Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speaker's ...

Samsung has been one of the known names in the Android tablet market. Its tablets are known for their impressive displays, sleek design, and much more. So now, here are all the reasons why Samsung ...

The Samsung Galaxy Tab S10 Ultra delivers everything you could reasonably ask from a high-end Android tablet, including a fantastic OLED screen, killer specs, and even a bundled stylus.

The Galaxy Tab A9 Plus is a solid budget tablet with a great display, sturdy design, and a decent update commitment from Samsung that should see the device supported through Android 16 at least.

Please verify your email address. I've had reservations about the Samsung Galaxy Tab Ultra since its introduction, and now that I've finally spent weeks testing the Tab S10 Ultra, I can ...

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Akebia Therapeutics Inc. (AKBA) on Thursday reported a loss of $20 million in its third quarter. The Cambridge, Massachusetts-based company said ...